propagation-seeding-biomarkers

MDS 2026 — Alpha-Synuclein Propagation & Seeding Biomarkers

Congress: Movement Disorder Society (MDS) International Congress 2026 Dates: October 4-8, 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Theme: Understanding Aging in Movement Disorders

Overview

MDS 2026 — Alpha-Synuclein Propagation & Seeding Biomarkers

Congress: Movement Disorder Society (MDS) International Congress 2026 Dates: October 4-8, 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Theme: Understanding Aging in Movement Disorders

Overview

The alpha-synuclein propagation and seeding biomarker track at MDS 2026 represents one of the most actively evolving areas in Parkinson's disease (PD) research. With seed amplification assays (SAA) transitioning from research tools to clinically validated diagnostics, and propagation mechanisms increasingly well-characterized, this year's sessions are expected to showcase significant advances in biomarker-driven patient management and therapeutic development["@pezzullo2024"].

This page provides comprehensive coverage of:

• Seed amplification assay clinical validation and kinetic analysis
• Propagation mechanisms and cellular uptake pathways
• Prodromal PD detection and disease staging
• Peripheral biomarker development (skin, blood)
• Alpha-synuclein PET imaging advances
• Therapeutic implications for disease modification

Seed Amplification Assays: Clinical Translation

Technology Overview

Alpha-synuclein seed amplification assays (αSyn-SAA) detect pathological, aggregated alpha-synuclein using the inherent prion-like property of pathogenic species to template the conversion of recombinant substrate[@pezzullo2024]. The two primary formats:

RT-QuIC (Real-Time Quaking-Induced Conversion)

RT-QuIC exploits cyclic shaking to accelerate seeded aggregation:

• Principle: Pathological seeds catalyze the conversion of normal α-syn monomers into amyloid fibrils
• Detection: Thioflavin T fluorescence monitors amyloid formation in real-time
• Sensitivity: 85-95% for Parkinson's disease CSF
• Specificity: 90-98% in healthy controls

PMCA (Protein Misfolding Cyclic Amplification)

PMCA uses sonication instead of shaking:

• Principle: Sonication fragments fibrils, creating new seed ends that accelerate conversion
• Sample types: CSF, tissue samples, peripheral tissues
• Performance: Comparable to RT-QuIC

Kinetic Analysis: Beyond Positive/Negative

Advanced kinetic analysis provides diagnostic and prognostic information beyond simple binary results[@orru2025]:

| Kinetic Parameter | Clinical Interpretation |
|-----------------|------------------------|
| Lag time | Time to detectable aggregation - correlates inversely with seed concentration |
| Maximum fluorescence (Fmax) | Reflects total fibril mass produced |
| Slope (Vmax) | Aggregation rate - may predict disease progression rate |
| Area under curve (AUC) | Integrated measure of seeding activity |

Clinical Validation at MDS 2026

Expected highlights from clinical validation studies:

Prodromal PD Detection

The RBD Window

REM sleep behavior disorder (RBD) represents the strongest prodromal marker for synucleinopathies[@iranzoweinberg2025]:

• Conversion rate: ~80-90% of individuals with idiopathic RBD eventually develop a synucleinopathy
• Seeding positivity: αSyn-SAA positive in 85-95% of idiopathic RBD cases
• Lead time: Seeding detectable up to 10-15 years before clinical PD diagnosis

Biomarker Staging Model

| Stage | Clinical Status | SAA Result | Seed Concentration |
|-------|----------------|------------|-------------------|
| Preclinical | Asymptomatic genetic risk | Variable | Low |
| Prodromal | RBD, hyposmia, autonomic | Positive | Moderate |
| Early PD | Motor symptoms < 2 years | Positive | High |
| Established PD | Motor symptoms > 2 years | Positive | Highest |
| Advanced PD | Dementia, falls | Positive | Variable |

MDS 2026 Expected Advances

Key developments in prodromal detection:

• Population screening: Feasibility of SAA-based screening in at-risk populations
• Genetic stratification: Combining genetic risk scores with SAA
• Multiplex panels: Simultaneous detection of α-syn, tau, β-amyloid seeds

Propagation Mechanisms

Cell-to-Cell Transmission

Alpha-synuclein exhibits prion-like properties, spreading between neurons and propagating pathology throughout the nervous system[@valera2023]. Key mechanisms:

Release Pathways

| Pathway | Description | Therapeutic Target |
|---------|-------------|-------------------|
| Exocytosis | Activity-dependent release via synaptic vesicles | Reduce neuronal hyperexcitability |
| Exosomes | Extracellular vesicles containing pathological species | Block exosome release |
| Direct membrane translocation | Pore-like formation | Stabilize membranes |
| Lysosomal exocytosis | Release following lysosomal permeabilization | Restore lysosomal function |

Cellular Uptake

[Neurons](/cell-types/dopaminergic-neurons-parkinsons) and glia take up extracellular alpha-synuclein through:

• Receptor-mediated endocytosis: LRP1, LRP2 (megalin), MHC-I, TLR2
• Clathrin-dependent pathways: Bulk endocytic uptake
• Direct membrane penetration: Oligomeric species
• Synaptic vesicle-mediated uptake: Endocytosis at synapses

Strain Biology

Distinct "strains" - conformational variants - exhibit different biological properties[7]:

• PD strains: Characteristic robust seeding in CSF
• MSA strains: Different conformational properties, lower detection rates
• DLB strains: Intermediate patterns between PD and MSA

Factors Influencing Propagation

| Factor | Effect on Propagation | Therapeutic Implication |
|--------|---------------------|----------------------|
| SNCA multiplication | Accelerated | ASO therapy |
| A53T mutation | Accelerated | Aggregation inhibitor |
| GBA mutation | Enhanced vulnerability | Enzyme enhancement |
| LRRK2 G2019S | Enhanced exosome release | LRRK2 inhibitor |
| Age | Declining clearance | General proteostasis boost |

Peripheral Biomarker Development

Skin Biopsy SAA

Skin biopsy represents a minimally invasive approach to detect pathological alpha-synuclein[@wang2026]:

Technique

| Parameter | Specification |
|-----------|---------------|
| Biopsy Sites | Posterior cervical, anterolateral thigh |
| Punch Size | 3-4mm diameter |
| Processing | Fibroblast culture + RT-QuIC |
| Turnaround | 2-4 weeks |
| Sensitivity | 85-92% (PD) |
| Specificity | 90-96% |

Clinical Applications

###血浆 SAA

Blood-based testing remains technically challenging due to:

• Low concentration of pathological species
• Presence of interfering proteins
• High background of normal alpha-synuclein

Other Peripheral Tissues

| Tissue | Detection Rate | Utility |
|--------|-------------|---------|
| Submandibular gland | 70-85% | Research |
| Colonic mucosa | 60-75% | Research |
| Olfactory mucosa | 75-85% | Research |

Alpha-Synuclein PET Imaging

Current Status

First-generation alpha-synuclein PET ligands are in clinical development[@kantarci2024]:

Challenges

Expected Updates at MDS 2026

• First-in-human PET ligand results
• Validation in post-mortem tissue
• Correlation with SAA and CSF biomarkers
• Longitudinal changes with disease progression

Therapeutic Implications

Targeting Propagation

Strategies to halt alpha-synuclein spreading include[@brundin2024]:

Small Molecule Inhibitors

• Anle138b: Oligomer modulator - Phase 1/2
• SynuClean-D: Prevents α-syn fibrillation
• EPI-589: Redox-active molecule

Immunotherapies

• Prasinezumab (RO7046015): Phase 2 showed reduced progression
• Cinpanemab (BIIB054): Phase 2 subgroup analysis
• PD01A (Affiris): Active immunization

Gene Therapy

• ASOs: Targeting SNCA expression
• CRISPR-based: Gene editing for SNCA, LRRK2

Clinical Trial Enrichment

SAA enables biomarker-driven patient selection:

• Enrichment: Selecting SAA-positive patients improves trial power
• Stratification: Kinetic parameters may predict progression
• Monitoring: Treatment response assessment

Session Highlights at MDS 2026

Expected presentations:

Cross-Links to Related Content

Mechanism Pages

• [Alpha-Synuclein Propagation Mechanism](/mechanisms/alpha-synuclein-propagation)
• [Prion-Like Spreading Hypothesis](/mechanisms/prion-like-propagation-hypothesis)
• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)

Biomarker Pages

• [Alpha-Synuclein Seed Amplification](/biomarkers/alpha-synuclein-seed-amplification)
• [Alpha-Synuclein Seeding Assay](/biomarkers/alpha-synuclein-seeding-assay)
• [Alpha-Synuclein Seed Kinetics (PD)](/biomarkers/alpha-synuclein-seed-kinetics-pd)
• [Skin Biopsy for Phosphorylated Alpha-Synuclein](/biomarkers/skin-biopsy-phosphorylated-alpha-synuclein-tau)

Disease Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Prodromal Parkinson's Disease](/diseases/prodromal-parkinsons)
• [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)

Therapeutic Pages

• [Alpha-Synuclein Immunotherapies](/therapeutics/alpha-synuclein-immunotherapies)
• [SAA-Guided Alpha-Synuclein Therapy](/therapeutics/saa-guided-alpha-synuclein-therapy)

MDS 2026 Related Sessions

• [MDS 2026 — Parkinson's Disease Sessions](/events/mds-2026-parkinsons-sessions)
• [MDS 2026 — Alpha-Synuclein & Lewy Body Research](/events/mds-2026-alpha-synuclein-lewy-body)
• [MDS 2026 — Diagnostics & Biomarkers](/events/mds-2026-parkinsons-diagnostics-biomarkers)

Key Sessions at MDS 2026

MDS 2026 will feature dedicated sessions covering:

References

External Links

• [MDS Congress 2026](https://www.mdscongress.org)
• [Michael J. Fox Foundation - Alpha-Synuclein Research](https://www.michaeljfox.org/)
• [Parkinson's Progression Markers Initiative (PPMI)](https://www.ppmi-info.org/)